NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Compass Group Diversified Holdings, LLC ("Compass Diversified" or the "Company") (NYSE: CODI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Compass Diversified investors who were adversely affected by alleged securities fraud between May 1, 2024 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Compass Group Diversified Holdings, LLC (NYSE: CODI). Shareholders who purchased shares of CODI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/compass-diversified-loss-submission-form/?id=148466&from=3 CL ...

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Compass Group Diversified Holdings, LLC (NYSE: CODI).Shareholders who purchased shares of CODI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/compass-diversified-loss-submission-form/?id=148444&from=4CLASS PERI ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Compass To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Compass stock or options between May 1, 2024 and May 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 14, 202 ...

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for failing to disclose material information, leading to significant financial losses for investors during the class period from May 1, 2024, to May 7, 2025 [1][3]. Group 1: Lawsuit Details - Investors who purchased securities of Compass during the class period have until July 8, 2025, to file lead plaintiff applications [1][2]. - The lawsuit alleges that Compass and certain executives violated federal securities laws by not disclosing critical information [3]. - Following the announcement of an internal investigation and the need to restate financial statements for fiscal 2024, Compass's share price dropped approximately 62%, from $17.25 on May 7, 2025, to $6.55 on May 8, 2025 [4]. Group 2: Company Background - Compass Diversified Holdings is currently under scrutiny due to irregularities identified in its subsidiary, Lugano Holding, Inc., related to financing, accounting, and inventory practices [4]. - The Audit Committee of Compass's Board has initiated an investigation after concerns were raised about Lugano's financial practices [4]. - Kahn Swick & Foti, LLC, the law firm handling the case, is recognized as one of the top securities litigation firms in the nation, serving various clients seeking recoveries for investment losses [5].

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Compass Diversified Holdings (“CODI” or the “Company”) (NYSE: CODI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether CODI and certain of it ...

Core Insights - The article expresses cautious optimism regarding Compass Therapeutics (NASDAQ: CMPX) and highlights the importance of an upcoming readout that is expected to occur early in the year [1]. Company Analysis - Compass Therapeutics is under scrutiny for its clinical trials and the potential implications of the results on its stock performance [1]. - The author has a background in biochemistry and extensive experience in analyzing biotech companies, which adds credibility to the insights shared about Compass Therapeutics [1]. Industry Context - The article emphasizes the significance of understanding the science behind biotech investments, suggesting that investors should conduct thorough due diligence to avoid pitfalls in this sector [1].

Core Viewpoint - A class action lawsuit has been filed against Compass Diversified for allegedly making false and misleading statements regarding its financial practices and internal controls during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Central District of California on behalf of all individuals and entities who purchased Compass securities between May 1, 2024, and May 7, 2025 [1]. - Investors have until July 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against the Company - The lawsuit claims that Compass's subsidiary, Lugano Holdings, Inc., had unrecorded financing arrangements and irregularities in its sales, cost of sales, inventory, and accounts receivable [3]. - It is alleged that these irregularities rendered the financial statements of Compass unreliable and would necessitate a restatement [3]. - The company is accused of failing to maintain adequate internal controls related to its financial statements, leading to materially false and misleading public statements [3].

Core Viewpoint - Compass Diversified (CODI) is under investigation for potential securities fraud and unlawful business practices following the disclosure of irregularities in its subsidiary, Lugano Holding, Inc. [1][2] Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of CODI regarding possible securities fraud or unlawful business practices [1] - On May 7, 2025, CODI announced a non-reliance on its financial statements for fiscal 2024 due to an ongoing internal investigation into Lugano Holding [2] - The Audit Committee of CODI's Board of Directors initiated an investigation after concerns were raised about Lugano's inventory financing practices, which identified irregularities in non-CODI financing, accounting, and inventory practices [2] Group 2: Financial Impact - Following the announcement of the investigation, CODI's stock price dropped by $10.70 per share, representing a decline of 62.03%, closing at $6.55 per share on May 8, 2025 [2]

Core Viewpoint - A class action lawsuit has been filed against Compass Group Diversified Holdings LLC due to alleged failures in financial reporting and internal controls, leading to significant stock price decline following the revelation of these issues [1][3][4]. Company Summary - The lawsuit, Nicholas Moreno v. Compass Group Diversified Holdings LLC, was initiated for investors who acquired securities between May 1, 2024, and May 7, 2025 [1]. - Allegations include the company's lack of effective internal controls over financial reporting and failure to disclose critical information regarding its subsidiary, Lugano Holding, Inc., which had undisclosed financing arrangements and irregularities in financial metrics [3]. - On May 7, 2025, Compass announced that its fiscal 2024 financial statements could no longer be relied upon due to an internal investigation into Lugano, leading to the resignation of Lugano's CEO without severance [4]. Market Impact - Following the announcement of the investigation, Compass' stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025, indicating a dramatic loss in market value [5].